MetAP2 Inhibitor APL-1202 clinical trials
Also written APL-1202.
How each study uses MetAP2 Inhibitor APL-1202 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the MetAP2 Inhibitor APL-1202 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- APL-1202
- 2
Studies by the year they started
7 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Jiangsu Yahong Meditech Co., Ltd aka Asieris (5) · Asieris Pharmaceuticals (AUS) Pty Ltd. (1) · Asieris Pharmaceutical Technologies Co., Ltd. (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Protease Inhibitors source
Studies
Open first, then newest update. How each study uses MetAP2 Inhibitor APL-1202 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy VolunteersNot yet recruitingPhase 1Jiangsu Yahong Meditech Co., Ltd aka AsierisNCT06034015Written as APL-1202 and APL-1501 (Single ascending dose)
- A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC PatientsRecruitingPhase 3Jiangsu Yahong Meditech Co., Ltd aka AsierisNCT04736394Written as APL-1202
- A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder CancerStatus unknownPhase 1/2Jiangsu Yahong Meditech Co., Ltd aka AsierisNCT04813107Written as APL-1202 in combination with tislelizumab
- Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) PatientsStatus unknownPhase 3Jiangsu Yahong Meditech Co., Ltd aka AsierisNCT04490993Written as APL-1202 in combination with Epirubicin
- A Phase I, Two-phase, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APL-1501 ER TabletsCompletedPhase 1Asieris Pharmaceuticals (AUS) Pty Ltd.NCT04601766Written as APL-1202+APL-1501 ER Tablets 3+APL-1501 ER Tablets 2
- Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG TherapyCompletedPhase 2Jiangsu Yahong Meditech Co., Ltd aka AsierisNCT04498702Written as APL-1202 treatment
- Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG TreatmentCompletedPhase 1/2Asieris Pharmaceutical Technologies Co., Ltd.NCT03672240Written as APL-1202